Page 32 - Shimadzu Journal vol.9 Issue1
P. 32
Providing precision and personalised medicine
for Singaporeans
One in four adult Singaporeans suffers from hypertension, which is
a leading cause of heart disease and strokes. It is now understood
that hypertension is due to either excessive vasoconstriction (tight-
ening of blood vessels) or excess salt and blood volume. Precise
measurements of hormones can identify which spectrum of hyper-
tension a patient has, and which medications are best suited for
that patient.
In recent years, hormone measurements also identify many
patients with a treatable and curable form of hypertension (Pri-
3
Shimadzu–CGH Clinomics Centre (SC )–powered by UFMS and Analytical mary Aldosteronism).
Intelligence (AI)
Achieving faster turnaround time for test results
With the SC , it is envisioned that clinical tests based on the
3
LC-MS/MS technology for adult diseases will no longer need to
be routinely sent to overseas centres for processing. By developing
the capability to conduct such tests in Singapore, local and even
regional patients can receive their test results with a significant re-
duction in waiting time from approximately two weeks to one or
two days.
Serving as a regional reference centre
In the long term, the SC aims to offer validated tests to patients in
3
Singapore as a clinical laboratory and to serve as a regional refer-
DPM Heng views the mass spectrometer at the Centre
ence centre in Asia Pacific for developing mass spectrometry solu-
tions for wider clinical applications for chronic conditions and other
areas of clinical diagnostics, such as drug monitoring. Measuring
Changi General Hospital
https://www.cgh.com.sg/pages/home.aspx the efficacy of medication for patients with other common condi-
tions, such as diabetes, can allow for more personalised treatment
options, which can lead to better patient outcomes.
Finally, Mr Prem Anand, Executive Officer and Senior General
Manager, Shimadzu (Asia Pacific) very eloquently summarised the
initiative and road ahead “Today, precision and personalised medi-
cines are being fuelled by the merger between analytical and med-
ical technologies. These technologies are more relevant today than
ever before, as more and more researchers are now using them
concurrently. The fact that Shimadzu is the only company in the
world to be a leader in both analytical and medical technologies,
gives us the unique opportunity to develop truly synergistic solu-
tions for Advanced Healthcare”
The launch of this Shimadzu–CGH Clinomics Centre is yet an-
other reiteration of how we all can collaborate towards Contributing
to Society Through Science and Technology.
Shimadzu Journal vol.9 Issue1 31
